Literature DB >> 2372662

Vasopressin and the pathogenesis of chronic renal failure.

D P Brooks1, H A Solleveld, L C Contino.   

Abstract

1. Partial (5/6) renal ablation was performed in Long Evans rats treated with vehicle or a vasopressin V1-receptor antagonist, in control Long Evans rats, and in homozygous Brattleboro rats which lack endogenous vasopressin. 2. In control and vasopressin-blocked Long Evans rats, 3 weeks following partial renal ablation, systolic blood pressure was 215 +/- 5 and 199 +/- 9 mmHg and, urinary protein excretion was 54 +/- 4 and 50 +/- 3 mg day-1, respectively. 3. The pressor response to exogenous vasopressin was significantly (P less than 0.05) reduced in rats treated with the V1-receptor antagonist (ED50 mmHg 5.0 +/- 1.6 vs. 0.09 +/- 0.01 micrograms kg-1). 4. In control Long Evans and in Brattleboro rats, 3 weeks following renal ablation, systolic blood pressure was 204 +/- 10 and 191 +/- 7 mmHg, and urinary protein excretion was 97 +/- 27 and 71 +/- 5 mg day-1, respectively. 5. Histological examination of the remaining kidney tissue demonstrated significant glomerular hyalinization following renal ablation but no differences between any of the groups. 6. The data indicate that neither vasopressin nor the urinary concentrating mechanism is likely to be involved in the hypertension and proteinuria associated with partial renal ablation.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2372662      PMCID: PMC1917451          DOI: 10.1111/j.1476-5381.1990.tb12055.x

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  12 in total

Review 1.  Role of vasopressin in cardiovascular regulation.

Authors:  L Share
Journal:  Physiol Rev       Date:  1988-10       Impact factor: 37.312

2.  Glomerular hemodynamic changes vs. hypertrophy in experimental glomerular sclerosis.

Authors:  Y Yoshida; A Fogo; I Ichikawa
Journal:  Kidney Int       Date:  1989-02       Impact factor: 10.612

3.  The importance of vasopressin in the development and maintenance of DOC-salt hypertension in the rat.

Authors:  J T Crofton; L Share; R E Shade; W J Lee-Kwon; M Manning; W H Sawyer
Journal:  Hypertension       Date:  1979 Jan-Feb       Impact factor: 10.190

4.  Metabolic clearance rate of immunoreactive vasopressin in man.

Authors:  M Benmansour; M Rainfray; F Paillard; R Ardaillou
Journal:  Eur J Clin Invest       Date:  1982-12       Impact factor: 4.686

5.  Vasopressin receptors from cultured mesangial cells resemble V1a type.

Authors:  S Jard; C Lombard; J Marie; G Devilliers
Journal:  Am J Physiol       Date:  1987-07

6.  Vasopressin in the rat with partial nephrectomy-salt hypertension.

Authors:  W J Lee-Kwon; L Share; J T Crofton; R E Shade; B Brooks; E E Muirhead; M Manning; W H Sawyer
Journal:  Clin Exp Hypertens       Date:  1981       Impact factor: 1.749

7.  Vasopressor role of ADH in the pathogenesis of malignant DOC hypertension.

Authors:  J Möhring; B Möhring; M Petri; D Haack
Journal:  Am J Physiol       Date:  1977-03

8.  AVP-induced Ca fluxes and contraction of rat glomerular mesangial cells.

Authors:  K Takeda; H Meyer-Lehnert; J K Kim; R W Schrier
Journal:  Am J Physiol       Date:  1988-07

9.  Arginine vasopressin promotes growth of rat glomerular mesangial cells in culture.

Authors:  M B Ganz; S K Pekar; M C Perfetto; R B Sterzel
Journal:  Am J Physiol       Date:  1988-11

10.  [1-beta-Mercapto-beta,beta-cyclopentamethylenepropionic acid),2-(O-methyl)tyrosine ]argine-vasopressin and [1-beta-mercapto-beta,beta-cyclopentamethylenepropionic acid)]argine-vasopressine, two highly potent antagonists of the vasopressor response to arginine-vasopressin.

Authors:  M Kruszynski; B Lammek; M Manning; J Seto; J Haldar; W H Sawyer
Journal:  J Med Chem       Date:  1980-04       Impact factor: 7.446

View more
  1 in total

1.  Vasopressin in chronic kidney disease: an elephant in the room?

Authors:  Vicente E Torres
Journal:  Kidney Int       Date:  2009-11       Impact factor: 10.612

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.